AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30487748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus everolimus
Number of subjects: 269
Study 30487748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Number of subjects: 269
Study 30487937 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (≥12,000 steps/day)
Number of subjects: 13
Study 30487937 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (<12,000 steps/day)
Number of subjects: 13
Study 30487982 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > 30)
Number of subjects: 14753
Study 30487982 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI 25-30)
Number of subjects: 14753
Study 30487984 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating biomarker panel (109 proteins measured in blood)
Number of subjects: 1244
Study 30487984 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic model incorporating clinical and biomarker results
Number of subjects: 1244
Study 30487998 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2015 (50 mg subcutaneously, once weekly for 24 weeks)
Number of subjects: 376
Study 30487998 — intervention group
Group type: COMPARATOR
Intervention: ETN (50 mg subcutaneously, once weekly for 24 weeks)
Number of subjects: 376
Study 30487998 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2015
Number of subjects: 376
Study 30487998 — intervention group
Group type: COMPARATOR
Intervention: ETN
Number of subjects: 376
Study 30488179 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (5 g/m2) individualized dosing using a fixed algorithm with 0-2 rate adjustments based on methotrexate levels during infusion
Number of subjects: 54
Study 30488265 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropulse laser trabeculoplasty (MLT)
Number of subjects: 27
Study 30488420 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS)
Number of subjects: 0
Study 30488420 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography-Computed Tomography (PET/CT)
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: CT in thoracic nodal groups (a and b)
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT in thoracic nodal groups (a and b)
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS in thoracic nodal groups (a and b)
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: All tests in abdominal nodal groups
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: All imaging techniques
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement among imaging techniques
Number of subjects: 101
Study 30496443 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 101
Study 30496579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy Fat-Free Mass Index (PP-FFMI)
Number of subjects: 43
Study 30496579 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational Weight Gain (GWG)
Number of subjects: 43
Study 30496579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy Fat Mass Index (PP-FMI)
Number of subjects: 43
Study 30496606 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of RANK/RANKL/OPG pathway
Number of subjects: 0
Study 30497143 — intervention group
Group type: EXPERIMENTAL
Intervention: INPH patients
Number of subjects: 102
Study 30497143 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 102
Study 30497166 — intervention group
Group type: EXPERIMENTAL
Intervention: SB623 cells
Number of subjects: 18
Study 30497179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-frequency ultrasound (UHF-US) Doppler imaging during movement
Number of subjects: 4
Study 30497179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-frequency ultrasound (UHF-US) Doppler imaging immediately after movement's termination
Number of subjects: 4
Study 30497198 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3
Study 30497397 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage system (Rapid Emergency Triage and Treatment System - RETTS)
Number of subjects: 571
Study 30497397 — intervention group
Group type: COMPARATOR
Intervention: No formal triage system
Number of subjects: 571
Study 30497431 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with 10 Gy directed to the involved mediastinum/hilar stations and/or positive surgical margins, followed by adjuvant systemic therapy.
Number of subjects: 10
Study 30497431 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with 30 Gy to the primary tumor for the unresectable patient.
Number of subjects: 10
Study 30497513 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI)
Number of subjects: 3166
Study 30497513 — intervention group
Group type: COMPARATOR
Intervention: No thrombus aspiration (no-TA) during primary percutaneous coronary intervention (PPCI)
Number of subjects: 3166
Study 30497513 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) during PPCI
Number of subjects: 3166
Study 30497513 — intervention group
Group type: COMPARATOR
Intervention: No thrombus aspiration (no-TA) during PPCI
Number of subjects: 3166
Study 30497557 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve replacement (TPVR)
Number of subjects: 309
Study 30497829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program based on physical training (24 sessions, supervised, three times a week, including aerobic training in treadmill and resistance training for upper limbs and lower limbs)
Number of subjects: 60
Study 30497926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 0
Study 30498390 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI 5 g BID for 3 weeks
Number of subjects: 15
Study 30498390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30498564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 0.25 mg/kg once daily
Number of subjects: 25
Study 30498564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 0.5 mg/kg once daily
Number of subjects: 25
Study 30498564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 0.75 mg/kg once daily
Number of subjects: 25
Study 30498564 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2-week run-in)
Number of subjects: 25
Study 30498576 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multimodal assessment including Questionnaire, Sports Concussion Assessment Tool 3, Balance Error Scoring System, Computerised Neurocognitive Testing, Vestibulo-ocular assessment, King Devick test, Graded exercise test, Blood tests, Neck strength, FitBit.
Number of subjects: 211
Study 30498576 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline testing at the Sports Surgery Clinic, Dublin (SSC) before the rugby season commences.
Number of subjects: 211
Study 30498824 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvers (n=40)
Number of subjects: 300
Study 30498824 — intervention group
Group type: COMPARATOR
Intervention: Non-Improvers (n=138)
Number of subjects: 300
Study 30498824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic (n=122)
Number of subjects: 300
Study 30499198 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherectomy
Number of subjects: 430
Study 30499198 — intervention group
Group type: COMPARATOR
Intervention: No Atherectomy
Number of subjects: 430
Study 30499360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir for 12 weeks
Number of subjects: 119
Study 30499605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (standard dose)
Number of subjects: 16329
Study 30499605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (reduced dose)
Number of subjects: 16329
Study 30499605 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (standard dose)
Number of subjects: 16329
Study 30499605 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (reduced dose)
Number of subjects: 16329
Study 30499734 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% intravenous immunoglobulin (IVIG; Flebogamma) administered at 1 g/kg over two consecutive days
Number of subjects: 64
Study 30499797 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized handoff protocol requiring bedside clinician communication using an information template.
Number of subjects: 165
Study 30499797 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized handoff protocol for new ICU patients.
Number of subjects: 165
Study 30499797 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized handoff protocol (overall).
Number of subjects: 165
Study 30500139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2160
Study 30500141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2160
Study 30500141 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 2160
Study 30501490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 93
Study 30501550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (15 to 20 mg/kg/day for 6 months, followed by dose escalation)
Number of subjects: 635
Study 30501550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 635
Study 30501869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyper-CVAD and ponatinib (45 mg per day for the first 14 days of cycle 1, then reduced to 30 mg per day at cycle 2, and further to 15 mg once a complete molecular response was achieved)
Number of subjects: 76
Study 30501869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyper-CVAD and ponatinib (maintenance with ponatinib daily at 30 mg or 15 mg, vincristine 2 mg intravenously on day 1, and prednisone 200 mg orally on days 1-5 monthly for 2 years)
Number of subjects: 76
Study 30501870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m²) with lenalidomide and dexamethasone (VRd) plus panobinostat (10 mg)
Number of subjects: 55
Study 30501870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m²) with lenalidomide and dexamethasone (VRd) plus panobinostat (15 mg)
Number of subjects: 55
Study 30501916 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake in normal weight children (859.0 ± 195.9 mg)
Number of subjects: 221
Study 30501916 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 221
Study 30503187 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in BUN ≥20% during hospitalization for AHF
Number of subjects: 247
Study 30503187 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 247
Study 30503187 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective decongestion
Number of subjects: 247
Study 30503846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbland blue (NBB) post-EMR defect features including size, number, and herniation of submucosal vessels.
Number of subjects: 501
Study 30503846 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal vessels in the left-sided colon segment.
Number of subjects: 501
Study 30503846 — intervention group
Group type: COMPARATOR
Intervention: Presence of visible vessels, their diameter, herniation, or other nonvascular PED features.
Number of subjects: 501
Study 30503909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation (CA) assessment at T1, T2, and T3; ARI values recorded: T1 (5.6 ± 1.7), T2 (3.9 ± 1.7), T3 (5.5 ± 1.8)
Number of subjects: 67
Study 30503909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic cerebral autoregulation (CA) assessment
Number of subjects: 67
Study 30503967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low literacy level instructions and reminder calls
Number of subjects: 4916
Study 30503967 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4916
Study 30503967 — intervention group
Group type: EXPERIMENTAL
Intervention: Properly processed samples
Number of subjects: 4916
Study 30503967 — intervention group
Group type: EXPERIMENTAL
Intervention: Improperly processed samples
Number of subjects: 4916
Study 30505290 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0
Study 30505484 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ARDS prediction score (MAPS)
Number of subjects: 677
Study 30505484 — intervention group
Group type: COMPARATOR
Intervention: Lung injury prediction score (LIPS)
Number of subjects: 677
Study 30505830 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0
Study 30505830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic supplementation)
Number of subjects: 0
Study 30506110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trastuzumab (H IV) treatment
Number of subjects: 3733
Study 30506283 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized PRRT (adjusted injected activity to deliver a prescribed absorbed dose to the kidney)
Number of subjects: 52
Study 30506283 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized PRRT
Number of subjects: 52
Study 30506309 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home spirometry and accelerometry during the peri-diagnostic period
Number of subjects: 180
Study 30506309 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home spirometry and accelerometry
Number of subjects: 180
Study 30506309 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) assessed prior to or during site visits
Number of subjects: 180
Study 30506341 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PDN
Number of subjects: 37
Study 30506341 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 30506361 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (aqueous dispersion of a novel silylated polyol)
Number of subjects: 70
Study 30506361 — intervention group
Group type: COMPARATOR
Intervention: Reference product (pyrethrum-based pediculicide)
Number of subjects: 70
Study 30506361 — intervention group
Group type: COMPARATOR
Intervention: Reference product (dimethicone)
Number of subjects: 70
Study 30506533 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (2 cycles of CapeOX or 3 cycles of mFOLFOX6) followed by elective surgery
Number of subjects: 62
Study 30506533 — intervention group
Group type: COMPARATOR
Intervention: Elective surgery without neoadjuvant chemotherapy
Number of subjects: 62
Study 30507862 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated office blood pressure (AOBP) measurement
Number of subjects: 1208
Study 30507862 — intervention group
Group type: EXPERIMENTAL
Intervention: Quintiles of AOBP distributions
Number of subjects: 1208
Study 30507862 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked hypertension phenomena
Number of subjects: 1208
Study 30507862 — intervention group
Group type: EXPERIMENTAL
Intervention: White-coat hypertension phenomena
Number of subjects: 1208
Study 30507862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower systolic AOBP
Number of subjects: 1208
Study 30508064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated both current and prior season
Number of subjects: 0
Study 30508064 — intervention group
Group type: COMPARATOR
Intervention: Vaccinated current season only
Number of subjects: 0
Study 30508064 — intervention group
Group type: COMPARATOR
Intervention: Not vaccinated current and prior season
Number of subjects: 0
Study 30508064 — intervention group
Group type: COMPARATOR
Intervention: Vaccinated prior season only
Number of subjects: 0
Study 30508076 — intervention group
Group type: EXPERIMENTAL
Intervention: RLD group (lead placement at the site of longest right-to-left electrical delay)
Number of subjects: 211
Study 30508076 — intervention group
Group type: EXPERIMENTAL
Intervention: RLD group
Number of subjects: 211
Study 30508076 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS width during RV pacing
Number of subjects: 211
Study 30508189 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 2778
Study 30508189 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARD monotherapy
Number of subjects: 2778
Study 30508189 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs + MTX
Number of subjects: 2778
Study 30508189 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs + other csDMARDs
Number of subjects: 2778
Study 30508189 — intervention group
Group type: COMPARATOR
Intervention: bDMARDs (all groups)
Number of subjects: 2778
Study 30508189 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 2778
Study 30508189 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy and bDMARDs
Number of subjects: 2778
Study 30508548 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigmented Facial Lesion Scale
Number of subjects: 0
Study 30508620 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse-planned, multibeam intensity modulated radiation therapy (IMRT)
Number of subjects: 113
Study 30509206 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear thermometer (Braun Thermoscan Pro 4000®)
Number of subjects: 599
Study 30509218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Childbirth and Parenting (MBCP) Program
Number of subjects: 16
Study 30509262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition care improvements implemented in five hospital units over one year (2016).
Number of subjects: 126
Study 30509262 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to sustain changes in nutrition care practices.
Number of subjects: 126
Study 30509262 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to spread nutrition care improvements.
Number of subjects: 126
Study 30509262 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies that supported both sustaining and spreading improvements.
Number of subjects: 126
Study 30509296 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 9867
Study 30509296 — intervention group
Group type: COMPARATOR
Intervention: Successful cfDNA assay without heparin
Number of subjects: 9867
Study 30509296 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of autoimmune disease
Number of subjects: 9867
Study 30509296 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester combined screening
Number of subjects: 9867
Study 30509296 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight
Number of subjects: 9867
Study 30509296 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (in vitro experiments)
Number of subjects: 9867
Study 30509869 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 10
Study 30510081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 30510361 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 429
Study 30510361 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 429
Study 30510439 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD patients
Number of subjects: 126
Study 30510439 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 126
Study 30510505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin, dosage and duration not specified
Number of subjects: 0
Study 30510505 — intervention group
Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study 30510509 — intervention group
Group type: EXPERIMENTAL
Intervention: HR7056
Number of subjects: 63
Study 30511200 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-114 combined with S-1, administered orally under fasting conditions at doses ranging from 5-240 mg/m
Number of subjects: 0
Study 30511337 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/androgen effects on sex-related differences in myocardial ischemia
Number of subjects: 0
Study 30511337 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiographic reperfusion indexes
Number of subjects: 0
Study 30511337 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet biology differences between men and women with IHD
Number of subjects: 0
Study 30511337 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to percutaneous coronary intervention, platelets, sex hormones, and myocardial damage at baseline
Number of subjects: 0
Study 30511990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting enriched with stromal vascular fraction
Number of subjects: 5
Study 30512189 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily until disease progression or study discontinuation
Number of subjects: 411
Study 30513489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for HD participants, 16 weekly sessions.
Number of subjects: 81
Study 30513489 — intervention group
Group type: COMPARATOR
Intervention: Nonclinical control group, 16-week waiting period.
Number of subjects: 81
Study 30514267 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-driven registry to facilitate patient transitions between primary and oncology care
Number of subjects: 500
Study 30514267 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-locating a nurse practitioner trained in care coordination within a complex care team
Number of subjects: 500
Study 30514267 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing teamwork through coaching
Number of subjects: 500
Study 30514287 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 3000
Study 30514326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lognormal distribution analysis of postpartum blood loss
Number of subjects: 0